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Abstract 
Unilateral axillary lymphadenopathy is a frequent mild side effect of COVID‑19 vaccination. European Society of Breast 
Imaging (EUSOBI) proposes ten recommendations to standardise its management and reduce unnecessary additional 
imaging and invasive procedures: (1) in patients with previous history of breast cancer, vaccination should be per‑
formed in the contralateral arm or in the thigh; (2) collect vaccination data for all patients referred to breast imaging 
services, including patients undergoing breast cancer staging and follow‑up imaging examinations; (3) perform 
breast imaging examinations preferentially before vaccination or at least 12 weeks after the last vaccine dose; (4) in 
patients with newly diagnosed breast cancer, apply standard imaging protocols regardless of vaccination status; (5) in 
any case of symptomatic or imaging‑detected axillary lymphadenopathy before vaccination or at least 12 weeks after, 
examine with appropriate imaging the contralateral axilla and both breasts to exclude malignancy; (6) in case of axil‑
lary lymphadenopathy contralateral to the vaccination side, perform standard work‑up; (7) in patients without breast 
cancer history and no suspicious breast imaging findings, lymphadenopathy only ipsilateral to the vaccination side 
within 12 weeks after vaccination can be considered benign or probably‑benign, depending on clinical context; (8) 
in patients without breast cancer history, post‑vaccination lymphadenopathy coupled with suspicious breast finding 
requires standard work‑up, including biopsy when appropriate; (9) in patients with breast cancer history, interpret and 
manage post‑vaccination lymphadenopathy considering the timeframe from vaccination and overall nodal meta‑
static risk; (10) complex or unclear cases should be managed by the multidisciplinary team.
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• Post-vaccination COVID-19 lymphadenopathy has 
been reported in up to 16% of cases.
• Breast imaging should be performed before or 
12 weeks after the last dose of vaccine.
• European Society of Breast Imaging (EUSOBI) pro-
vides ten recommendations to manage COVID-19 
post-vaccination unilateral axillary lymphadenopa-
thy.
Background
Alongside staple preventive measures such as physi-
cal distancing, consistent use of face masks, prompt 
deployment of testing, tracing and isolation proto-
cols [1], a quick and effective rollout of vaccination 
campaigns throughout the world represents the key 
element to contain the SARS-CoV-2 pandemic and 
begin a transition towards normal social and eco-
nomic activity [2–4]. As of July 27, 2021, the World 
Health Organization lists 292 candidate vaccines in 
clinical development, 184 in the pre-clinical phase and 
108 in the clinical phase [5]. The European Commis-
sion, through the European Medicines Agency, has 
up to now issued four conditional marketing authori-
sations for vaccines developed by Pfizer–BioNTech, 
Moderna, AstraZeneca, and Janssen Pharmaceuticals 
[6, 7]. These companies used different development 
strategies, including messenger RNA (mRNA)-based 
and adenovirus vector-based vaccines, and proposed 
different vaccination programs (Table  1). Despite the 
unquestionable positive protective effect, a number of 
widespread local and systemic reactions, mostly mild 
and following the second dose, have been observed 
both in clinical trials and in the population-wide 
rollout of vaccines, the main being pain at the site 
of injection, ipsilateral axillary lymph node enlarge-
ment, tiredness, headache, and fever [7–9]. In this 
paper, we focus on the reaction which could have a siz-
able impact on breast imaging, namely axillary lymph 
node enlargement, and provide recommendations on 
the management of this side effect.
The pre‑COVID‑19 scenario
In breast imaging, axillary lymphadenopathy can be 
detected at mammography, digital breast tomosynthe-
sis, ultrasonography, magnetic resonance imaging (MRI), 
and chest computed tomography or positron emission 
tomography/computed tomography staging exams, 
being potentially related to a wide spectrum of benign 
(e.g., mastitis, breast abscess, infected skin lesions, cat-
scratch fever) and malignant (e.g., breast cancer, lym-
phoma, melanoma, ovarian cancer) conditions [10, 11]. 
According to the 2013 edition of the American College 
of Radiology Breast Imaging Reporting and Data System 
(ACR  BI-RADS) Atlas [11], isolated unilateral axillary 
lymphadenopathy without underlying abnormal breast 
findings or known infection or inflammation should be 
considered suspicious (BI-RADS 4 category). In this sce-
nario, an additional imaging work-up to rule out breast 
cancer is recommended and, if negative, fine-needle 
aspiration or core biopsy of the enlarged lymph node 
should be performed. Of note, occult primary breast can-
cer presenting with lymph node metastases but negative 
conventional imaging accounts for up to 1% of all breast 
cancers [12, 13], although in 75–85% of cases the cancer 
is detectable on breast MRI [14, 15].
The post‑COVID‑19 scenario and the relationship 
with vaccination
Just as lymphadenopathy is a common feature of severe 
COVID-19 presentation [16], lymph node swelling is a 
common side effect of vaccinations that evoke a robust 
immune response [17, 18] and has been described after 
COVID-19 vaccination in the axilla ipsilateral to the 
injected deltoid muscle [19]. In the phase III trial of the 
Moderna vaccine [20], palpable axillary lymphadenopa-
thy ipsilateral to the vaccination arm was reported in 
11.6% of recipients after the first dose and in 16.0% 
of recipients after the second dose, occurring within 
2–4 days and with a median duration of 1–2 days. Con-
versely, in the phase III trial of the Pfizer–BioNTech 
vaccine [21], lymphadenopathy was reported in 0.3% of 
recipients, occurred within 2–4 days, and lasted approxi-
mately 10 days. Notably, both these trials reported only 
Table 1 Main characteristics of the four COVID‑19 vaccines approved in Europe as of July 28, 2021
Developer Commercial name Type Number of doses Dosage interval
Pfizer–BioNTech Comirnaty mRNA‑based 2 3–12 weeks
Moderna COVID‑19 Vaccine Moderna mRNA‑based 2 4 weeks
AstraZeneca Vaxzevria Adenovirus vector‑based 2 4–12 weeks
Johnson and Johnson ‑ Janssen 
Pharmaceuticals
COVID‑19 Vaccine Janssen Adenovirus vector‑based 1 –
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clinically assessed lymphadenopathy and probably under-
estimated the rate of subclinical lymphadenopathy, which 
could be detected by imaging [22]. Of note, a recent study 
on 169 positron emission tomography–computed tomog-
raphy examinations has revealed that as many as 29% of 
examined patients still showed avid uptake of fluorode-
oxyglucose in ipsilateral lymph nodes 7–10  weeks after 
the second dose of the Pfizer–BioNTech vaccine [23]. 
Since the beginning of the vaccination campaigns in the 
USA and Europe, several case series have described lym-
phadenopathy presenting both as a palpable mass or as 
an incidental finding during routine breast imaging after 
COVID-19 vaccination [24–27].
Thus, when facing an incidental or symptomatic unilat-
eral axillary lymphadenopathy, while malignancy remains 
the most critical aetiology, COVID-19 vaccination needs 
to be recognised as a potential differential diagnosis. 
Examples of axillary lymphadenopathy after COVID-19 
vaccination are presented in Figs. 1 and 2.
Recommendations
Since worldwide mass vaccination campaigns against 
COVID-19 are currently underway, breast radiologists 
should be aware of reactive axillary lymphadenopathy 
as a possible side effect of vaccination, to limit patients’ 
anxiety and  avoid unnecessary diagnostic imaging 
and invasive procedures. We carefully considered the 
Recommendations for the Management of Axillary 
Adenopathy in Patients with Recent COVID-19 Vacci-
nation [28]  issued by the Society of Breast Imaging, the 
statements by Becker et al. [22], Edmonds et al. [29], and 
Lehman et al. [30, 31].
EUSOBI provides the following recommendations 
regarding general issues (number 1, 2), asymptomatic 
subjects, including women attending screening programs 
(number 3), cases with symptoms or imaging-detected 
findings (number 4–9), and complex cases (number 10).
 1. In patients with previous history of breast cancer, 
vaccine injection (both doses for two-doses vac-
cines) should be performed in the contralateral 
arm or in the anterolateral thigh.
 2. COVID-19 vaccination data (vaccination status, 
date, dose, injection site) of all patients presenting 
for breast imaging with any modality should be col-
lected and made available to radiologists, including 
the cases of breast imaging performed for cancer 
staging and of follow-up imaging examinations.
 3. Breast examinations should be preferentially per-
formed before the first dose of a COVID-19 vac-
cine or at least 12  weeks after the injection. For 
vaccines with a two-dose schedule, the 12-weeks 
rule applies from the day of the second injection.
 4. In patients newly diagnosed with breast cancer, all 
necessary breast imaging examinations with any 
modality must be performed without any delay due 
Fig. 1 Ultrasonography of the left axilla showing an enlarged 17 mm reactive lymph node in a 45‑year‑old woman about a week after receiving 
the first dose of the Vaxzevria COVID‑19 vaccine. Note the asymmetrical cortical thickening (white arrow) associated with a well‑represented central 
fatty hilum
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to vaccination, taking into consideration the risk of 
false positive lymph node findings.
 5. The contralateral axilla and both breasts should 
be clinically examined using appropriate imaging 
to exclude malignancy in all patients with axillary 
symptoms and in all cases of imaging-detected uni-
lateral axillary lymphadenopathy before vaccina-
tion or at least 12 weeks after.
 6. In patients with or without previous breast cancer 
history, imaging-detected suspicious axillary lym-
phadenopathy contralateral to the vaccination side 
should be managed according to standard work-up 
protocols, including, when necessary, tissue sam-
pling.
 7. In patients without breast cancer history and 
no suspicious breast imaging findings, imaging-
detected unilateral axillary lymphadenopathy on 
the same side of recent COVID-19 vaccination (i.e., 
within 12  weeks) should be managed according 
to the clinical setting (Table  2). In asymptomatic 
patients it should be classified as a benign finding 
(BI-RADS 2) and no further work-up should be 
pursued. In case of patients reporting symptoms 
of axillary lymphadenopathy more than 12 weeks 
after vaccination, ultrasound examination of the 
axilla is recommended. In patients with axillary 
symptoms, incidental unilateral axillary lymphad-
enopathy ipsilateral to the vaccination side without 
any suspicious finding in the breast should be clas-
sified as a probably benign finding (BI-RADS 3), 
requiring a 12-week follow-up. In case of persistent 
suspicion at this 12-week follow-up, ACR BI-RADS 
recommendations for the management of axillary 
lymphadenopathy should be followed, with further 
work-up including, when necessary, tissue sam-
pling [11].
 8. In patients without breast cancer history, incidental 
unilateral axillary lymphadenopathy after COVID-
19 vaccination coupled with ipsilateral suspicious 
findings in the breast at any imaging modality 
should be managed according to clinical practice, 
including biopsy when appropriate [11].
Fig. 2 Screening mammography performed in a 44‑year‑old woman with a positive family history for breast cancer (mother and aunt), bearing 
implants for aesthetic purposes. Mammography (a) was considered negative. Breast ultrasonography was also performed because of her family 
history and high breast density (ACR category d). While ultrasonography was negative for both breasts, multiple round, enlarged, hypoechoic lymph 
nodes (measuring up to 1 cm in axial diameter), with a thickened (< 3 mm) cortex, were seen in the left axilla (b). There were no skin changes and 
there was no history of any infection or trauma. On the right side, axillary lymph nodes were normal. Because of her family history and the presence 
of breast implants, magnetic resonance imaging was performed (c T2‑weighted short‑time inversion recovery; d fat‑sat contrast‑enhanced 
T1‑weighted gradient‑echo; e apparent diffusion coefficient map). No suspicious mass or non‑mass lesions were seen in both breasts. Implants 
showed no signs of rupture (not shown). In the left axilla, multiple enlarged lymph nodes were well visible in c and d (red circles); on the apparent 
diffusion coefficient map (e, red circle), they mainly exhibited low signal (restricted diffusivity). When an ultrasound‑guided biopsy of the most 
suspicious lymph node was proposed, the patient mentioned that she had a Comirnaty COVID‑19 vaccination one week before in the left arm. 
The attending radiologist was more than surprised to hear this, as at that time, a COVID‑19 vaccination was only administered to people older than 
70 years. Follow‑up performed four weeks after the second vaccination was negative and showed no residual enlarged lymph nodes
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 9. In patients with personal breast cancer history, 
lymphadenopathy after vaccination should be 
interpreted considering the time since vaccination 
and overall nodal metastatic risk (cancer type, loca-
tion, stage, etc.) [32]. For patients at low risk of axil-
lary or supraclavicular nodal metastases in whom 
the lymphadenopathy is overwhelmingly more 
likely due to the vaccination than to the underlying 
neoplasm (considering time frame, pain, type, and 
location of cancer), a cautious management strat-
egy without default follow-up imaging is appropri-
ate. Short-interval follow-up imaging with ultra-
sonography (with at least a 12-week delay) may 
be performed in patients with higher risk of meta-
static lymphadenopathy (e.g., breast  cancer, head 
and neck cancer, upper extremity/trunk melanoma 
or lymphoma). Node biopsy should be considered 
in the setting of high nodal metastatic risk when 
immediate histopathologic confirmation is neces-
sary for timely patient management.
 10. All complex or unclear cases (e.g., axillary lym-
phadenopathy ipsilateral to the cancer and the side 
of vaccination within 12 weeks after vaccination in 
patients with previous bilateral breast cancer; vac-
cinations performed on different sides) should fol-
low a personalised management, considering the 
risk of malignant lymphadenopathy, opting for tis-
sue sampling when appropriate after multidiscipli-
nary team discussion.
Recommendation number 3 could be difficult to be 
applied in organised population-based screening pro-
grams. In this case, we suggest to carefully apply rec-
ommendation number 2.
These recommendations should be applied to both 
female and male patients. The latter, of course, do not 
undergo breast cancer screening with the exception of 
BRCA2 mutation carriers, who could be included in 
high-risk screening programs [33].
Of note, sites for vaccination alternative to the proxi-
mal arm (such as the thigh) [31] could be considered to 
avoid most breast care-related problems ensuing from 
the current vaccine administration practice.
Conclusions
Since the rollout of COVID-19 vaccines is rapidly pro-
ceeding, radiologists will increasingly encounter in their 
practice COVID-19 vaccination-induced lymphad-
enopathy detected by breast imaging [19]. Moreover, 
the emergence of new SARS-CoV-2 variants and the 
unclear durability of vaccine-induced immunity [34] will 
likely lead to re-vaccination or to the administration of 
new vaccines, further extending this issue. Thus, further 
research and adherence to evidence-based recommenda-
tions are paramount to standardise the management of 
these findings, avoiding unnecessary additional imaging 
and invasive procedures.
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Table 2 Management of incidental unilateral axillary lymphadenopathy after recent (within 12 weeks) COVID‑19 vaccination
BI-RADS Breast Imaging Reporting and Data System, ACR American College of Radiology
Patients Clinical context Management
Without any 
history of breast 
cancer
No symptoms
No suspicious breast findings at 
imaging
Unilateral axillary lymphadenopathy ipsilateral to the vaccination side should be classified as 
a benign (BI‑RADS 2) finding and no further work‑up should be pursued. Ultrasonography 
should be performed in case of symptoms of axillary lymphadenopathy more than 12 weeks 
after vaccination
Breast imaging for breast symp‑
toms
No suspicious breast findings at 
imaging
Unilateral axillary lymphadenopathy ipsilateral to the vaccination side should be classified 
as a probably benign (BI‑RADS 3) finding, and clinical follow‑up of the axilla is indicated. In 
case of symptoms of axillary lymphadenopathy more than 12 weeks after vaccination, ACR 





Any context Avoid vaccination at the breast cancer side. Manage unilateral axillary lymphadenopathy ipsi‑
lateral to the vaccination side according to overall nodal metastatic risk. For patients at low 
risk, define a case‑by‑case cautious management strategy. For patients at high risk, perform 
short‑interval follow‑up imaging with ultrasonography with at least a 12‑week delay post 
vaccination, with node biopsy when necessary
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